Shire’s $30bn move on Baxalta

Pharma giant Shire has made an unsolicited $30bn all-share offer for America’s Baxalta.

15-8-6-Shire-634

Shire is testing investors' tolerance

Pharmaceuticals giant Shire, Dublin-based and UK-listed, has made an unsolicited $30bn all-share offer for America's Baxalta. Shire said a tie-up with Baxalta would produce a group with $20bn in sales by 2020. Shire's shares fell on the news. The pharma mergers and acquisitions boom shows no sign of cooling: $400bn of transactions have been announced since January, 80% up from the same period in 2014.

What the commentators said

But there's also "a fair slug of industrial logic", said Neil Unmack on breakingviews.com. Putting the two groups together should produce a strong presence in haemophilia, and as it grows its global presence, it will gain the scale to invest in new drugs, boost prices and beef up marketing, with a view to becoming a leader in rare disease drugs. Yet Shire shareholders seem unconvinced, said Helen Thomas in The Wall Street Journal.

One worry is that Baxalta's haemophilia drugs, which account for half of sales, are about to face competition. What's more, the price is worth a hefty 16 times operating earnings, and is only likely to go higher as negotiations get underway. Shire's recent appetite for "ever bigger, more risky dealmaking is testing investors' tolerance".

Recommended

Three winners of the long-term biotech boom
Share tips

Three winners of the long-term biotech boom

Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…
22 Mar 2021
The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Four investment trusts for income investors to buy now
Investment trusts

Four investment trusts for income investors to buy now

Some high-yielding listed lending funds have come through the crisis with flying colours. David Stevenson picks four of the best.
12 Apr 2021
Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021